65,437 trials
Androgen Receptor Positive · Estrogen Receptor Negative · HER2/Neu Negative
Primary: Response Rate (Complete Response or Partial Response) — 1; 1; 2; 12 Participants
Cataract
Primary: Change From Baseline (Preoperative Exam) in Macular Thickness — 4.91; 1.30 microns
Covid19
Primary: Area Under the Curve (AUC) of Shedding of SARS-CoV-2 Virus — 95.3; 93 cycles*days — p=0.89
Cancer
Primary: PedsQL 3.0 Cancer Module Scale — 71.59 score on a scale
Fallopian Tube Carcinoma · Fallopian Tube Clear Cell Adenocarcinoma · Fallopian Tube Endometrioid Adenocarcinoma
Primary: Number of Participants With Treatment Success — 23 Participants
Stroke, Acute · Aphasia
Primary: YNQ Score — 0; 1; 0; 1 Participants
Diabetic Macular Edema
Primary: Change in Optical Coherence Tomography Central Subfield Thickness From Baseline to 4 Months — 13; 15 microns
Acute Lymphoblastic Leukemia
Primary: Part 1: Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) and SHP-674-Related TEAEs During the Tolerability Assessment Period — 3; 3 Participants
Hypertension · Self-management · Technology
Primary: Change in Systolic and Diastolic Blood Pressure — 0.55; -2.17; -0.80; -1.04 mm Hg
Esophageal Cancer
Primary: Dose of Radiation Delivered to 90% of Tumor Volume (D90) — 105.5 percentage of Prescription dose
Prostate Cancer
Primary: Number of Participants With Any Grade or High Grade (Gleason Score 7 or Higher) Prostate Cancer as Measured by Histopathology — 11; 8 Participants
Rectal Cancer
Primary: Correlation Between Ploidy Status With Local Recurrence of Cancer — 3; 31; 14; 92 Participants
Inadequate; Pulmonary Ventilation, Newborn · Infant, Very Low Birth Weight
Primary: Change in Partial Pressure of Carbon Dioxide on Capillary Blood Gas — 0.019 mm Hg
Wrinkle · Fine Lines · Crepey Skin
Primary: Subject Satisfaction — 7; 21; 15; 4 Participants
Hereditary Hemochromatosis
Primary: Effect of LJPC-401 Versus Placebo on Blood Iron Levels — -32.8; -2.5 Percent Change — p=< 0.0001